Financing ·
Regentis Biomaterials Ltd. entered into definitive securities purchase agreements on June 17, 2026, to issue and sell…
RGNTRegentis Biomaterials Ltd.
Regentis Biomaterials Ltd. entered into definitive securities purchase agreements on June 17, 2026, to issue and sell 1,844,543 ordinary shares and pre-funded warrants to accredited and institutional investors. The offering includes ordinary warrants to purchase up to 1,857,143 shares at a combined price of $3.50 per share and warrant, or $3.4999 for pre-funded warrants. Expected gross proceeds are approximately $6.5 million, with the offering anticipated to close around June 23, 2026. Net proceeds will fund the GelrinC clinical trial, FDA pre-market approval preparations, Gelrin technology platform optimization, manufacturing scale-up, and European market entry. ThinkEquity LLC is serving as the exclusive placement agent. Regentis Biomaterials Ltd. is a biotechnology company developing biomaterial technologies.